Detected ·
MyoPax
——
Berlin-based biotech MyoPax has received investment through IBB Ventures' B# Plus fund to advance its CRISPR/Cas-based gene-repair platform for muscle-wasting diseases.
- Website
- —
- linkedin.com/company/86304529
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-14 04:10:12 UTC
- Signal ID
- fba31c6a-efa8-4a39-b181-0d86aef02b9a
As the API returns it
{
"id": "fba31c6a-efa8-4a39-b181-0d86aef02b9a",
"created_at": "2026-10-14T04:10:12.281239Z",
"company_name": "MyoPax",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/86304529",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Berlin-based biotech MyoPax has received investment through IBB Ventures' B# Plus fund to advance its CRISPR/Cas-based gene-repair platform for muscle-wasting diseases.*"
}